|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Evotec_AG
gptkb:Bayer_Health_Care
gptkb:Bristol-Myers_Squibb
gptkb:Company
gptkb:Pfizer
gptkb:National_Park
gptkb:Evotec
|
|
gptkbp:acquired
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:acquisition
|
gptkb:Juno_Therapeutics
gptkb:Celgene_Cellular_Therapeutics
2019-01-03
$74 billion
Acquired by Bristol-Myers Squibb
|
|
gptkbp:ceo
|
gptkb:Mark_J._Alles
|
|
gptkbp:clinical_trial
|
gptkb:healthcare_organization
gptkb:drug
oncology
hematology
immunology
solid tumors
|
|
gptkbp:community_engagement
|
gptkb:hospital
patient advocacy
research institutions
|
|
gptkbp:employees
|
7,000 (2019)
|
|
gptkbp:focus
|
gptkb:healthcare_organization
oncology
hematology
immunology
Inflammatory Diseases
|
|
gptkbp:founded
|
gptkb:1986
|
|
gptkbp:founder
|
gptkb:Sol_J._Barer
|
|
gptkbp:global_presence
|
over 70 countries
|
|
gptkbp:headcount
|
7,000 (2019)
|
|
gptkbp:headquarters
|
gptkb:Summit,_New_Jersey
gptkb:United_States
|
|
gptkbp:healthcare
|
biologics
small molecules
gene therapies
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Celgene
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:market_cap
|
$74 billion (2019)
|
|
gptkbp:partnership
|
Partnership with Juno Therapeutics
Partnership with Amgen
Abb Vie for Imbruvica
Amgen for Blincyto
Bristol-Myers Squibb for Opdivo
|
|
gptkbp:partnerships
|
gptkb:Bristol-Myers_Squibb
gptkb:Amgen
gptkb:Abb_Vie
|
|
gptkbp:products
|
gptkb:Lenalidomide
gptkb:Pomalidomide
gptkb:Thalidomide
gptkb:Revlimid
gptkb:Pomalyst
gptkb:Thalomid
Idhifa
|
|
gptkbp:research_focus
|
gptkb:Gene_Therapy
genetic disorders
autoimmune diseases
Biologics
cancer therapies
Cellular Immunotherapy
|
|
gptkbp:revenue
|
$15.2 billion (2019)
|
|
gptkbp:subsidiary
|
gptkb:Juno_Therapeutics
gptkb:Celgene_Cellular_Therapeutics
|
|
gptkbp:sustainability_initiatives
|
community support
ethical practices
environmental responsibility
|
|
gptkbp:symbol
|
gptkb:CELG
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.celgene.com
|